Sienna Biopharmaceuticals, Inc. (SNNAQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSienna Biopharmaceuticals, Inc. (SNNAQ) trades at $0.0001. Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies in immunology and inflammation. The company filed for Chapter 11 bankruptcy in 2019, later converted to Chapter 7. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for SNNAQ: SNNAQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Sienna Biopharmaceuticals, Inc. (SNNAQ) Healthcare & Pipeline Overview
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted therapies for immunology and inflammation, particularly in dermatology. The company's pipeline includes treatments for psoriasis, atopic dermatitis, and acne, but its operations are currently impacted by Chapter 7 bankruptcy proceedings following an earlier Chapter 11 filing.
What Is the Investment Thesis for SNNAQ?
Investing in Sienna Biopharmaceuticals, Inc. presents significant risks due to its Chapter 7 bankruptcy status initiated in 2019. The company's pipeline, which included SNA-120, SNA-125, and SNA-001, held potential in the dermatology space, targeting conditions like psoriasis, atopic dermatitis, and acne. However, the bankruptcy proceedings have halted clinical trials and development efforts. The company's market capitalization is effectively zero, and the stock trades on the OTC market, indicating high speculation and uncertainty. Any investment decision would hinge on the remote possibility of a restructuring or asset sale that could provide minimal returns to shareholders, but the likelihood is extremely low given the Chapter 7 liquidation.
Based on FMP financials and quantitative analysis
SNNAQ Key Highlights
SNA-120, a TrkA inhibitor, was in Phase IIb clinical trials for psoriasis treatment.
- SNA-125, a topical JAK3 inhibitor, was in Phase I/II clinical trials for atopic dermatitis.
- SNA-001, a topical silver particle suspension, was in pivotal clinical trials for acne and hair reduction.
- The company filed for Chapter 11 bankruptcy on September 16, 2019, later converted to Chapter 7 on December 18, 2019.
- Market capitalization is effectively $0.00B due to bankruptcy.
Who Are SNNAQ's Competitors?
SNNAQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | — |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | — |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | — |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | — |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | — |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | — |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SNNAQ's Key Strengths?
Proprietary drug candidates targeting specific pathways in skin.
- Clinical-stage pipeline with potential for addressing unmet needs.
- Experienced management team in dermatology and drug development.
What Are SNNAQ's Weaknesses?
Chapter 7 bankruptcy status.
- Limited financial resources.
- Dependence on successful clinical trial outcomes and regulatory approvals.
What Are the Key Risks for SNNAQ?
Financial-distress signal — its Altman Z-Score of -9.50 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-59.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Chapter 7 bankruptcy liquidation.
- Complete loss of investment.
- Limited or no recovery for shareholders.
- Low liquidity and high volatility in the OTC market.
- Lack of financial transparency and regulatory oversight.
What Threats Does SNNAQ Face?
- Intense competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Unsuccessful clinical trial outcomes.
What Are SNNAQ's Competitive Advantages?
- Proprietary drug candidates (SNA-120, SNA-125, SNA-001).
- Targeted therapies with potential for improved efficacy and safety.
- Intellectual property protection for its drug candidates.
What Does SNNAQ Do?
Sienna Biopharmaceuticals, Inc., founded in 2010 and headquartered in Westlake Village, California, was a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies in the fields of medical dermatology and aesthetics. The company aimed to address unmet needs in areas such as psoriasis, atopic dermatitis, acne, and unwanted hair. Sienna's approach involved developing therapies that selectively target specific pathways in tissues, particularly the skin, to maximize efficacy and minimize systemic side effects. Its lead product candidates included SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A (TrkA), in Phase IIb clinical trials for psoriasis and associated pruritus; SNA-125, a topical dual Janus kinase 3 (JAK3) inhibitor in Phase I/II trials for atopic dermatitis, psoriasis, and pruritus; and SNA-001, a topical suspension of silver particles in pivotal clinical trials for acne and reduction of light-pigmented hair. However, on September 16, 2019, Sienna Biopharmaceuticals filed a voluntary petition for reorganization under Chapter 11 bankruptcy, which was later converted to Chapter 7 on December 18, 2019. This has significantly impacted the company's operations and future prospects.
What Products and Services Does SNNAQ Offer?
- Developed SNA-120, a TrkA inhibitor for psoriasis and pruritus.
- Developed SNA-125, a topical JAK3 inhibitor for atopic dermatitis, psoriasis, and pruritus.
- Developed SNA-001, a topical silver particle suspension for acne and hair reduction.
- Conducted Phase IIb clinical trials for SNA-120.
- Conducted Phase I/II clinical trials for SNA-125.
- Conducted pivotal clinical trials for SNA-001.
- Filed for Chapter 11 bankruptcy, later converted to Chapter 7.
How Does SNNAQ Make Money?
- Focused on developing and commercializing targeted therapies in dermatology.
- Out-licensed or partnered with other companies for commercialization.
- Sought to address unmet needs in psoriasis, atopic dermatitis, acne, and unwanted hair.
What Industry Does SNNAQ Operate In?
Sienna Biopharmaceuticals operated within the competitive biotechnology industry, specifically focusing on dermatology. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from established pharmaceutical companies and other emerging biotechs. The dermatology market is driven by the increasing prevalence of skin conditions like psoriasis, atopic dermatitis, and acne, creating demand for innovative therapies. However, Sienna's bankruptcy reflects the challenges faced by smaller biotech companies in securing funding and navigating the complexities of clinical development and regulatory approval.
Who Are SNNAQ's Key Customers?
- Patients with psoriasis, atopic dermatitis, and acne.
- Dermatologists and other healthcare professionals.
- Potential pharmaceutical partners for commercialization.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Sienna Biopharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.50 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Sienna Biopharmaceuticals, Inc. stands at -59.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -68.3%, showing how much profit it generates from its asset base. A current ratio of 2.07 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Sienna Biopharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Westlake Village, US. The company is led by CEO David E. I. Pyott. SNNAQ has traded publicly since 2017.
SNNAQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
SNNAQ Latest News
-
Stocks That Hit 52-Week Lows On Thursday
· Feb 27, 2020
-
Stocks That Hit 52-Week Lows On Tuesday
· Jan 21, 2020
SNNAQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SNNAQ.
Price Targets
Wall Street price target analysis for SNNAQ.
SNNAQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SNNAQ; grades run from A+ (80-100) to F (below 30).
Leadership: David E. I. Pyott
Managing Director
David E. I. Pyott served as the managing director of Sienna Biopharmaceuticals, overseeing a small team of 13 employees. His background includes experience in the pharmaceutical and healthcare industries.
Track Record: Due to the company's bankruptcy and limited available information, it is difficult to assess David Pyott's track record at Sienna Biopharmaceuticals. The company's failure to achieve sustainable financial stability and the subsequent Chapter 7 filing overshadow any potential achievements during his tenure. His leadership was ultimately unable to prevent the company's downfall.
SNNAQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sienna Biopharmaceuticals, Inc. does not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may be distressed, bankrupt, or have chosen not to comply with stricter regulations. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, OTC Other stocks often lack transparency and have limited regulatory oversight, increasing investment risk.
- OTC Tier: OTC Other
- Limited or no financial reporting.
- High risk of fraud or manipulation.
- Low liquidity and wide bid-ask spreads.
- Potential for delisting and loss of investment.
- Bankruptcy and potential liquidation.
- Verify the company's current legal status and bankruptcy proceedings.
- Review any available financial statements and disclosures.
- Assess the liquidity and trading volume of the stock.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Research the background and track record of the company's management.
- Determine if there is any potential for asset recovery or restructuring.
- Prior history as a Nasdaq-listed company (before delisting).
- Previous clinical trials and drug development efforts.
- Existing intellectual property related to drug candidates.
Sienna Biopharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What are the main risks for SNNAQ?
The primary risk for SNNAQ is the ongoing Chapter 7 bankruptcy liquidation. This means the company's assets are being sold to pay off creditors, and there is a very low probability of any recovery for shareholders.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available historical data and news reports.
- The company's bankruptcy status significantly impacts its current operations and future prospects.
- Investment in SNNAQ is highly speculative and carries a substantial risk of loss.